Introduction
Malignant melanoma represents a malignancy with most rapidly increasing incidences offering a poor prognosis for patients with metastatic disease (Lasithiotakis et al., 2006) . Melanomas develop and progress in a sequence of defined stages from nevic lesions or normal cells (Meier et al., 1998) . The primary melanoma is characterized by an early and invasive radial growth phase (RGP), which advances through the vertical growth phase (VGP) with competence for metastasis into metastatic melanoma (MM) and highly aggressive melanoma (HM) (Clark, 1991; Elder et al., 1993) . The metastatic stage represents a therapeutic challenge, because it remains largely chemo-and radio-resistant (Flaherty, 2006) , making alternative therapeutic strategies mandatory to achieve successful cancer treatment.
In this context, the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) seems promising, because of its apparently tumor-selective properties (Walczak et al., 1999) , preferentially inducing apoptosis in transformed cells while sparing primary cells (Wiley et al., 1995; Pitti et al., 1996; Kothny-Wilkes et al., 1998) . Earlier studies from our lab, however, revealed that tumor selectivity of TRAIL does not fully account for melanoma, as most cell lines investigated remained TRAIL resistant (Zeise et al., 2004) .
TRAIL can bind four different receptors. TRAIL-R1 (DR-4) and TRAIL-R2 (DR-5) transduce apoptotic signals by the engagement of an intracellular death domain (DD) and formation of the death-inducing signaling complex (DISC) by recruitment of the adapter protein Fas-associated with death domain and procaspase-8. Autocatalytic activation of initiator caspase-8 allows downstream activation of effector caspases including procaspase-3, finally executing apoptosis (Sprick et al., 2000) . TRAIL-R3 (DcR-1) and TRAIL-R4 (DcR-2) instead possess only a truncated death domain or completely lack the death domain, thereby acting as decoy receptors, interfering with TRAIL-mediated signaling and conferring TRAIL resistance (Merino et al., 2006) . However, the role of endogenously expressed decoy receptors in TRAIL resistance is still controversial. As only some TRAILresistant cell lines express decoy receptors, other molecules have been described to modulate TRAIL responsiveness.
TRAIL-induced apoptosis can be inhibited by the upregulation of anti-apoptotic proteins. Particularly, the high expression level of caspase-8 antagonist FLICE inhibitory protein (FLIP) has been attributed to TRAIL insensitivity (Ricci et al., 2004; Zeise et al., 2004; Panner et al., 2005; Geserick et al., 2007) . Downstream inhibition can be achieved by binding of the inhibitor of apoptosis proteins (IAPs) cIAPs and x-linked IAP (xIAP) to caspase-3, thereby preventing its final processing into the catalytically active fragment (Micheau and Merino, 2004) . Other mechanisms counteracting TRAIL responses involve constitutive activation of the Ras-PI3K (phosphoinositide-3 kinase)-AKT signaling pathway (Larribere et al., 2004; Meier et al., 2005) , finally leading to activation of the transcription factor nuclear factor-kB (NF-kB), which is considered to be the prototypic anti-apoptotic pathway (Amiri and Richmond, 2005) .
Besides the classical activators tumor necrosis factor or interleukin-1, TRAIL was also shown to trigger NFkB activation, thereby counteracting TRAIL-induced apoptosis (Falschlehner et al., 2007) . In its inactive stage, NF-kB is sequestered in the cytoplasm by interaction with the inhibitory protein IkBa (Li and Verma, 2002) . Liberation of NF-kB is mediated by activation of a multi-subunit IkB kinase complex, which subsequently catalyzes the phosphorylation of IkBa, leading to its polyubiquitination and proteasomal degradation (Delhase et al., 1999) . Released NF-kB translocates into the nucleus to activate responsive genes, among them those encoding anti-apoptotic proteins, such as FLIP, cIAPs and xIAP (Wang et al., 1998 (Wang et al., , 2002 Micheau et al., 2001) .
To overcome TRAIL resistance of tumor cells, combinatorial therapeutic strategies adding chemotherapeutic drugs and irradiation have been investigated (Ganten et al., 2006; Zhang et al., 2006; Koschny et al., 2007) . In an earlier study, we showed that irradiation with a sublethal ultraviolet light B (UVB) dose rendered a resistant melanoma cell line (IGR-37) highly sensitive toward TRAIL. Compared with the TRAILsensitive cell line (A-375), TRAIL resistance seemed to be related to FLIP S expression, and sensitization was shown to be mediated by UVB-induced downregulation of FLIP (Zeise et al., 2004) . In subsequent studies, we showed that co-stimulation of epithelial cells with interleukin-1 and UVB resulted in NF-kB-mediated repression of anti-apoptotic genes, including FLIP and cIAPs, thereby enhancing UVB-induced apoptosis (Po¨ppelmann et al., 2005; Strozyk et al., 2006) . As TRAIL induces NF-kB, co-stimulation with sublethal UVB may confer sensitization of TRAIL-resistant melanoma cells through downregulation of antiapoptotic genes.
This study was performed to investigate whether TRAIL susceptibility is related to or changes during tumor progression of melanoma. Therefore, 18 melanoma cell lines representing defined tumor progression stages (RGP, VGP, MM and HM) were investigated concerning TRAIL responsiveness and the ability to become sensitized by the co-application of sublethal UVB. Furthermore, the molecular mechanism(s) underlying UVB-induced TRAIL sensitization in different melanoma subtypes were studied. Identification of a common molecular mechanism would enable the establishment of new combinatorial therapies with TRAIL.
Results

Primary melanocytes are resistant even against high TRAIL doses
Analyses of TRAIL and UVB responses revealed primary melanocytes to be completely resistant even against 1000 ng/ml TRAIL as well as against irradiation with 200 or 400 J/m 2 UVB. Yet, the combination of moderate TRAIL concentrations (100 ng/ml) and UVB (200 J/m 2 ) did not result in induction of apoptosis. Only co-treatment with high TRAIL doses (500 ng/ml) plus UVB (400 J/m 2 ) caused cell death (Figure 1 ). ). Cells responding with less than 10% apoptosis were determined to be resistant (R). Cells showing up to 30% apoptosis were designated as sensitive (s), cells exceeding 30% apoptosis were referred to as highly sensitive (S). Apoptosis screenings revealed that 10 out of 18 cell lines remained resistant (R) against TRAIL, whereas 7 cell lines showed moderate sensitivity (s) and only 1 cell line, WM-793 (VGP), strongly responded (S) to TRAIL TRAIL susceptibility is independent of TRAIL receptor expression Among other mechanisms, TRAIL resistance has been attributed to differences in TRAIL-R expression patterns. Cells expressing mainly TRAIL-R2 were shown to be less sensitive toward soluble TRAIL than cells expressing TRAIL-R1 (Wajant et al., 2001) . In addition, expression of decoy receptors TRAIL-R3 and TRAIL-R4 was accredited to confer TRAIL resistance (Merino et al., 2006) . For the melanoma cell lines studied here, the expression pattern of all four TRAIL-Rs, as determined by FACS (fluorescence-activated cell sorting) analysis, did not clearly correlate with TRAIL responsiveness. On average, higher expression levels of TRAIL-R2 than TRAIL-R1 were detected. However, except for WM-1366 (VGP), TRAIL-sensitive cell lines expressed higher TRAIL-R2 levels. As low levels of death receptors may suffice to induce apoptosis, the relative contribution of TRAIL-R1 and TRAIL-R2 in apoptosis induction of sensitive cells remains unclear. This is evident when comparing SBCL-2 (RGP) with MeWO (MM), both showing similar apoptotic responses to TRAIL but expressing very divergent TRAIL-R1 and -R2 amounts (Table 1 and Supplementary Figure S1 ). Interestingly, most cell lines did not express remarkable amounts of decoy receptors, and if they did, it did not clearly translate to TRAIL resistance. Furthermore, TRAIL-induced receptor internalization remained unaffected by UVB (Supplementary Figure S2 ), indicating that TRAIL susceptibility is not exclusively determined at the level of TRAIL-R subtype expression but additionally requires intracellular modulations. Comparing the ratio of caspase-8/FLIP with caspase-3/ xIAP expression suggests the ratio of caspase-3/xIAP to predict TRAIL responsiveness To elucidate the mechanism underlying TRAIL resistance, we compared statuses of caspase-3/xIAP with caspase-8/FLIP L/S proteins. All cell lines expressed, if at all, very low FLIP S levels independent of TRAIL responsiveness. For only three cell lines, WM-1552C (RGP), 451-LU (HM) and 1205-LU (HM), elevated FLIP L expression correlated with TRAIL resistance or very low susceptibility, whereas eight resistant cell lines did not express elevated FLIP L (Figure 3 ). Caspase-8 expression was very similar throughout the cell lines investigated. Only for 3 out of 10 cell lines, WM-1819 (VGP), M5 (MM) and WM-852 (MM), lower caspase-8 levels might be correlated with TRAIL resistance. A closer look suggests that the ratio of caspase-3 and xIAP expression might be a key determinant of TRAIL susceptibility. In 7 out of 10 resistant cell lines, WM-1552C (RGP), WM-3211 (RGP), WM-115 (VGP), WM-1819 (VGP), M5 (MM), WM-852 (MM) and 1205-LU (HM), caspase-3 levels were significantly lower than xIAP levels. Vice versa, sensitive cell lines, WM-35 (RGP), SBCL2 (RGP), WM-793 (VGP), SKmel 19 (MM), MeWO (MM), 451-LU (HM), displayed lower xIAP levels than caspase-3 levels. As xIAP serves as an inhibitor for caspase-3, this might be causative for TRAIL resistance. If this is true, caspase-3-xIAP crosstalk might also be the nodal point for UVBinduced sensitization.
UVB-induced sensitization toward TRAIL coincides with xIAP degradation and full caspase-3 processing and activation Knowing the importance of FLIP as well as of xIAP in conferring TRAIL resistance, we investigated the impact of UVB on caspase-8/FLIP and on caspase-3/xIAP interplay as potential trigger of TRAIL sensitization. A clear pattern became apparent. After 6 h of stimulation, all sensitive cell lines showed caspase-8 processing and activation, whereas most of the TRAIL-resistant cell lines did not. However, three resistant cell lines (WM-115 (VGP), WM-3248 (VGP), MV3 (MM)) even revealed caspase-8 processing without showing activation ( Figure 4a ). FLIP levels remained constant. Costimulation of cells with UVB never resulted in the enhancement of caspase-8 processing and activation or in FLIP reduction, indicating UVB-induced sensitization not to be determined at the DISC level. Things seemed to be different at the capase-3/xIAP level. TRAIL-resistant cells showed either no processing of pro-caspase-3 or only into the catalytically inactive p21 fragment, coinciding with stable xIAP protein level and failure to gain caspase-3 activity ( Figure 4b ). Sensitive cell lines in contrast responded to TRAIL with at least partial processing of pro-caspase-3 into the catalytically active p17 fragment, coinciding with caspase-3 activity and partial xIAP degradation. Sublethal UVB alone had no impact on either xIAP or pro-caspase-3. Most revealing, in cells responding to combined UVB þ TRAIL treatment, induction of apoptosis was preceded by pronounced xIAP degradation, accompanied by enhanced caspase-3 processing into p17 and activation ( Figure 4b ). As TRAIL has been described to activate NF-kB, and xIAP is known to be controlled by NF-kB, TRAIL treatment may result in the NF-kB-dependent upregulation of xIAP, thereby conferring resistance. In contrast, NF-kB can convert from an activator into a repressor of anti-apoptotic genes in the presence of DNA-damaging agents (Campbell et al., 2004; Po¨ppelmann et al., 2005) . Accordingly, irradiation with sublethal UVB along with TRAIL treatment may sensitize cells to apoptosis by NF-kB-dependent transcriptional xIAP repression, causing enhanced decrease of xIAP protein, allowing pro-caspase-3 processing and the execution of apoptosis.
UVB-induced sensitization toward TRAIL coincides with NF-kB-dependent transcriptional xIAP repression
To assess the interrelation of NF-kB activation, xIAP expression and TRAIL sensitivity, we correlated IkBa degradation with xIAP transcription. Basal xIAP mRNA levels varied remarkably among the different cell lines and could not be directly assigned to TRAIL susceptibility ( Figure 5a ). Except for three cell lines, WM-1552C (RGP), WM-3211 (RGP) and 1205-LU (Figure 4b ). NF-kB activation had no apparent effect on xIAP transcription in cells expressing high basal levels, but was associated with elevated transcription in cells expressing low basal levels ( Figure 5a ). However, co-treatment of all cell lines rendered sensitive by UVB caused pronounced depletion of xIAP protein, paralleled by enhanced IkBa degradation ( Figure 4b ) and inhibition of xIAP transcription. This effect was not limited to xIAP expression but expanded to FLIP, another NF-kB-dependent gene (Figure 5a ). In contrast, expression of the NF-kB-irresponsive bax gene remained unaffected (Figure 5b ), indicating repression of xIAP and FLIP to be an active NF-kB-dependent process. The only exception was fully resistant WM-1152C (RGP) cells, showing neither IkBa nor xIAP degradation. Consequently, mRNA levels of xIAP remained unchanged. This observation even strengthens the implication that TRAIL þ UVB-induced IkBa degradation followed by NF-kB-dependent repression of xIAP is responsible for enhanced xIAP depletion and TRAIL sensitization. ) or TRAIL þ UVB as indicated. After 6 h, processing of proteins caspase-8 and FLIP L was documented by western blot analysis. Equal loading was monitored by reprobing the membrane with a b-actin antibody. In parallel, cellular protein extracts were subjected to caspase-8 activity assay using a specific fluorophor-coupled caspase-8 substrate (Ac-IETD-AMC) (b) After 6 h processing of xIAP, caspase-3 and IkBa were documented by western blot analysis. Equal loading was monitored by reprobing the membrane with a b-actin antibody. Caspase-3 activity was determined in parallel using a specific fluorophor-coupled caspase-3 substrate (Ac-DEVD-AMC). Data represent one out of three independently performed experiments. ) for 4 h. Subsequently, RNA was extracted and expression pattern of (a) x-linked inhibitor of apoptosis proteins (xIAP) and FLIP as well as of (b) bax was monitored by semiquantitative reverse transcriptase-PCR analysis against GAPDH. Data represent one out of three independently performed experiments.
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shown to antagonize TRAIL þ UVB-induced apoptosis, whereas knock down of xIAP resulted in strong sensitization to TRAIL (Figure 6 ). Death receptor-induced apoptosis mostly coincides with the proteasomal degradation of xIAP (Dohi et al., 2004; Shi et al., 2005; Sohn et al., 2006; Cheung et al., 2008) . Accordingly, TRAIL-sensitive cell lines responded with partial xIAP degradation and caspase-3 processing. We therefore addressed whether NF-kBdependent transcriptional repression contributes to xIAP-GFP xIAP-endog. ) alone or in combination with both stimuli. After 16 h, apoptosis was determined in a Cell Death Detection ELISA, and xIAP protein status was documented by western blot analysis. In addition, same cell lines transfected with either scrambled siRNA or xIAP siRNA were left untreated stimulated with TRAIL (100 ng/ml). After 16 h, apoptosis was determined in a Cell Death Detection ELISA, and xIAP protein status was documented by western blot analysis. Death ELISA reflects mean±s.d. of three independently performed experiments. Western blots represent one out of three independently performed experiments.
enhanced depletion of xIAP. Thus, co-treatment of cells overexpressing xIAP-GFP from a viral, not NF-kBdriven promoter with TRAIL þ UVB revealed endogenous xIAP to be significantly stronger reduced in comparison with ectopically expressed xIAP-GFP, indicating NF-kB-dependent repression of endogenous xIAP transcription to contribute to its overall cellular decline (Figure 7) . If NF-kB is the crucial molecule enforcing xIAP decrease, its inhibition by overexpression of a super-repressor IkBa variant (IkBa-SR) should counteract xIAP depletion as well as apoptosis. This was shown to be the case as IkBa-SR-expressing cells, representing each tumor progression stage, showed a reduced apoptotic phenotype and maintained higher xIAP protein levels (Figure 8 ).
Discussion
As melanocytes are very resistant to even high TRAIL doses in vitro, application of lower doses might be a basic approach to selectively eliminate melanoma. However, an earlier study from our group uncovered 
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that only a minor fraction out of a panel of melanoma cell lines is a priori TRAIL sensitive (Zeise et al., 2004) . We therefore asked whether TRAIL resistance of melanocytes might get lost during tumor development due to general molecular changes. A total of 10 completely TRAIL-resistant melanoma cell lines (out of 18 tested) were equally distributed between the 4 tumor progression stages investigated, indicating that TRAIL susceptibility is independent of the state of malignant transformation. Seven cell lines showed a rather weak apoptotic response to TRAIL treatment. To identify molecular targets preventing TRAIL-induced apoptosis, we applied a sublethal UVB dose as a model to sensitize melanoma cells. Irrespective of the tumor progression stage, co-treatment with TRAIL þ UVB always induced apoptosis in TRAILresistant and enhanced apoptosis in TRAIL-sensitive cell lines. In contrast, melanocytes remained unaffected, offering a potentially tumor-selective treatment. TRAIL susceptibility has been described to depend on decoy receptor expression (Degli-Esposti et al., 1997a, b; Merino et al., 2007) , but most of the studies were based on transient overexpression, questioning the physiological relevance. Other studies showed tumor cells to escape TRAIL-induced apoptosis by the upregulation of decoy receptors (Bouralexis et al., 2003; Riccioni et al., 2005) . However, this appears not to be the rule, and various endogenous mechanisms of TRAIL resistance are conceivable and discussed in the literature ( Geserick et al., 2007) . In this study, the TRAIL decoy receptor expression did not clearly correlate with TRAIL responsiveness. Furthermore, sensitivity toward soluble TRAIL, as used throughout this study, has been mainly attributed to TRAIL-R1 expression (Wajant et al., 2001 ). This was supported by the finding that high expression levels of TRAIL-R1 were characteristic for TRAIL sensitivity within seven melanoma cell lines investigated (Kurbanov et al., 2005) . In our study, no correlation between the relative TRAIL-R1 and TRAIL-R2 expressions and TRAIL susceptibility existed, strongly indicating that TRAIL responsiveness appears to be predominantly regulated at the intracellular level.
The major intracellular factors affecting TRAIL susceptibility in melanoma are the pro-and antiapoptotic interaction partners caspase-8 and FLIP L/S as well as caspase-3 and xIAP (Griffith et al., 1998; Chawla-Sarkar et al., 2004; Xiao et al., 2005) . The FLIP L/S expression is unlikely to account for TRAIL susceptibility of melanoma cells studied here, as expression profiles of FLIP L did not well correlate with TRAIL responsiveness. With three exceptions, the cleavage pattern of caspase-8 perfectly matched TRAIL susceptibility of individual cell lines. These specific cell lines did not respond with measurable activation or apoptosis induction to caspase-8 processing, indicating some inhibitory protein to prevent enzymatic activity. FLIP is unlikely to be the candidate, because it usually inhibits death receptor-induced apoptosis by preventing caspase-8 cleavage (Bullani et al., 2001) . Although FLIP L , the splicing variant predominantly expressed here, has also been implicated in the activation of caspase-8 at the DISC; this coincided with apoptosis induction (Micheau et al., 2002) , which is not the case in these three cell lines. Besides, cleavage pattern as well as activation statuses of caspase-8 remained largely unaffected by co-stimulation with UVB in all cell lines and left FLIP levels unaffected. These data strongly suggested TRAIL sensitization to be conducted at another level downstream of the DISC. A clear inverse correlation was discerned between caspase-3 and xIAP. Except for two cell lines, TRAIL-resistant cells expressed higher xIAP than caspase-3 levels, and in most cases the lower the caspase-3 levels were, the less sensitive the cells appeared. Corresponding to this, TRAIL-sensitive cell lines expressed lower xIAP than caspase-3 levels. xIAP is known to directly interact with caspase-3, thereby preventing full processing of the 33 kDa pro-form into the catalytically active 17 kDa fragment (Kashkar et al., 2003; Eckelman et al., 2006) and inhibiting the apoptotic effector machinery. Accordingly, differences in expression levels of these proteins may contribute to overall TRAIL responsiveness.
This important correlation was underlined by the fact that in TRAIL-resistant cells, constant xIAP protein levels correlated with, if at all, processing of caspase-3 only to the catalytically inactive p21 fragment, corresponding to a lack of enzymatic activity. Sensitization with UVB caused a decrease in xIAP level and resulted in full caspase-3 activation, also evident from processing . After 6 h, protein status of endogenous and ectopically expressed xIAP was documented by western blot analysis and relative expression levels were calculated using Image Quant software.
into the p17 fragment in all but one of the cell lines. This illustrates a common molecular mechanism underlying TRAIL sensitization. As shown for caspase-8 activation, TRAIL sensitization by UVB also did not reveal significant enhancement of caspase-9 activation (Supplementary Figure S3 ), indicating full caspase-3 processing and activation to underlie regulation different from enhanced activation of upstream initiator caspases. 
Proteasomal degradation of xIAP is a prerequisite for fast and efficient execution of death receptor-induced apoptosis (Sohn et al., 2006) , and resynthesis of xIAP is dependent on NF-kB-controlled transcription (Wang et al., 2002) . In this context, TRAIL has earlier been described to additionally trigger NF-kB activation, accounting for TRAIL resistance (Jeremias and Debatin, 1998; Franco et al., 2001; Ehrhardt et al., 2003) . Here, TRAIL treatment alone resulted at least in partial degradation of IkBa in almost every cell line. NF-kB activation consequently resulted in the upregulation of xIAP transcription or in continued high levels of xIAP mRNA in cells showing transient and constitutive NFkB activity, as it has been described to frequently occur during melanoma progression (Ueda and Richmond, 2006) . High xIAP protein levels may compensate its proteasomal degradation during induction of apoptosis (Kashkar et al., 2007) . Upon TRAIL sensitization by UVB, significantly enhanced IkBa degradation coincided with a decrease in xIAP at the protein as well as the mRNA level. The only exception being WM-1552C cells, which were shown to be completely resistant to even higher doses of TRAIL, UVB and the combined treatment. These cells neither showed xIAP or IkBa degradation, nor caspase-3 processing.
Earlier study from our group revealed that costimulation with interleukin-1 þ UVB converts NF-kB from an activator into a repressor of anti-apoptotic genes (Po¨ppelmann et al., 2005; Strozyk et al., 2006) . This functional switch has been associated with differentially phosphorylated NF-kB forms, interacting with transcription repressors instead of activators at certain promoters in response to genotoxic stress (Campbell et al., 2004) . Accordingly, upon co-stimulation with TRAIL þ UVB, activated NF-kB seems to turn into a repressor of xIAP as well as of FLIP. In principle, mechanisms apart from NF-kB-dependent repression may cause loss of xIAP and FLIP mRNAs, including UVB-induced enhancement of mRNA decay. This however seems to be unlikely, because the xIAP mRNA stability of actinomycin-treated cells remained unaffected by UVB alone but was significantly reduced upon TRAIL co-treatment (Supplementary Figure S4) . Furthermore, expression levels of NF-kB-irresponsive bax remained unchanged. Transcriptional repression, however, selectively enhances depletion of the cytosolic xIAP pool, which undergoes constant proteasomal degradation (Supplementary Figure S5) , thereby shifting the balance from an anti-to a pro-apoptotic state and allowing full caspase-3 processing and execution of TRAIL-induced apoptosis. Transcriptional repression of FLIP does not translate to the protein level within the 6 h of investigation. As full elimination of FLIP by transcriptional inhibition by actinomycin D in melanoma cells was shown to take up to 24 h (Griffith et al., 1998) , transcriptional repression may have a delayed and therefore inferior impact on TRAIL sensitization under these specific conditions.
The close NF-kB-xIAP-caspase-3 crosstalk could be further confirmed by showing that upon apoptotic TRAIL þ UVB treatment, ectopically expressed xIAP-GFP was significantly less diminished than endogenous xIAP. Whereas only endogenous xIAP expression underlies regulation by NF-kB and will therefore be repressed under the given conditions, xIAP-GFP will constantly be produced by the viral CMV promoter, thereby compensating proteasomal degradation and increasing steady-state xIAP levels. Correspondingly, the rate of TRAIL þ UVB-induced apoptosis could be reduced upon ectopic xIAP expression and, vice versa, cells were sensitized toward TRAIL-induced cell death by xIAP knockdown. As a formal proof of the importance of NF-kB in promoting apoptosis sensitivity, we showed that inhibition of NF-kB activation by overexpression of IkBa-SR significantly counteracted apoptosis and, most importantly, loss of xIAP protein.
Taken together, this study reveals TRAIL resistance of melanoma cells to be independent of the tumor progression stage. xIAP was identified as a central mediator of TRAIL resistance. Using sublethal UVB as a tool for TRAIL sensitization, we unraveled a proapoptotic role of NF-kB by inhibition of xIAP transcription. This ambivalent function of NF-kB emphasizes that inhibition of NF-kB as a general strategy in cancer therapy requires consideration of the specific cellular context. As this mechanism was found to be ubiquitous throughout the melanoma system investigated here, direct chemical xIAP inhibition or combinatorial treatment with DNA-damaging agents and TRAIL seems to offer new therapeutic implications to fight melanoma.
Materials and methods
Cells and reagents
A total of 18 human melanoma cell lines (WM-35, WM-1552C, SBCL2, WM-3211, WM-793, WM-115, WM-3248, WM-1366 , WM-1819 , SKmel 19, M5, WM-852, Mewo, IGR-39, MV3, 451-LU, 1205 and melanocytes were kindly provided by Friedegund Meier (Department of Dermato-Oncology, University of Tu¨bingen, Germany). Melanocytes were cultured in the Melanocyte Growth Medium Package (CellSystems Biotechnology, St Katharinen, Germany). Melanoma cells were maintained in RPMI 1640, 10% fetal bovine serum and 1% penicillin-streptomycin at 5 Â 10 5 cells/ml. Irradiation was performed in phosphatebuffered saline using a bank of six fluorescent bulbs (TL12, Phillips, Eindhoven, The Netherlands), emitting most of the energy within the UVB range (290-320 nm, emission peak: 313 nm). Recombinant human iz-TRAIL (Ganten et al., 2006) was kindly provided by Henning Walczak (Tumour Immunology Unit, Imperial College London, UK). For ectopic expression, 6.5 Â 10 6 WM-3211 cells were electroporated with 25 mg of plasmid-DNA: xIAP-pEGFPC3 or pBK-CMV-IkB-SR in 600 ml RPMI þ 10% fetal bovine serum þ 1.25% dimethyl sulfoxide and stimulated 24 h later. xIAP knockdown was facilitated by transfecting 6 Â 10 5 cells with 50 pmol siRNA: 5 0 -AUCCAUCCAUGGCAGAUUATT-3 0 using Lipofectamine 2000 (Invitrogen) 48 h prior to stimulation.
Determination of cell death
After 16 h, stimulation cells were harvested, and apoptosis was determined in a Cell Death Detection ELISA (Roche Diagnostics GmbH, Mannheim, Germany). Enrichment of mono-and oligonucleosomes is detected by biotinylated antihistone-and peroxidase-coupled anti-DNA antibodies and calculated as absorbance of sample/absorbance of control. An enrichment factor of 2 corresponds to 10% apoptotic cells as determined by Annexin V FACS analysis.
Flow cytometry analysis
Cells were resuspended in phosphate-buffered saline þ 1% bovine serum albumin at a final concentration of 2 Â 10 5 / 100 ml. Monoclonal mouse antibodies against TRAIL-Rs were provided by Amgen/Genentech (Seattle, WA, USA): anti-TRAIL-R1 (M271, IgG2a), anti-TRAIL-R2 (M413), anti-TRAIL-R3 (M430) and anti-TRAIL-R4 (M445, IgG1). Antibodies or isotype control mouse IgG1 of 1 mg (BD Biosciences, San Diego, CA, USA) were incubated for 1 h on ice. Cells were washed, resuspended in 100 ml phosphatebuffered saline þ 1% bovine serum albumin and stained with FITC-labelled rabbit anti mouse IgG (1:100, F9137; Sigma, St Louis, MO, USA) for 30 min on ice. Cells were washed, resuspended in 400 ml phosphate-buffered saline þ 1% bovine serum albumin and analysed by flow cytometry in an EPICS XL-MCL flow cytometer (Beckmann Coulter GmbH, Krefeld, Germany). Emitted green fluorescence (l max 520 nm) was detected using (FL-1) band pass filter. A total of 20 000 cells were analysed per sample, and data analysed with WIN/MDI 2.8 software.
Caspase activation assay Cells were lysed in lysis buffer (20 mM Tris, pH 7.4, 200 mM NaCl, 1% Igepal and Complete (Roche)) for 30 min on ice. After centrifugation, 15 mg cellular extract was combined with 50 ml activity buffer (220 mM mannitol, 68 mM sucrose, 10 mM Hepes (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), pH 7.4, 5 mM Na-Pyruvate, 2 mM NaCl, 2 mM MgCl 2 , 2.5 mM KH 2 PO 4 , 0.5 mM EGTA (ethylene glycol bis (b-aminoethylether)-N,N,N 0 ,N 0 ,-tetraacetic acid); 1 mM dithiothreitol, 0.1 mM phenylmethylsulfonyl fluoride) and 20 mM specific caspase-3 (Ac-DEVD-AMC) or caspase-8 (Ac-IETD-AMC; Axxora LLC, San Diego, CA, USA) substrate. Substrate turnover was measured every 15 min over a 2-h period in a FluoStar luminometer (BMG Lab Technologies, Durham, NC, USA) with excitation of 390 nm and emission of 460 nm. n-Fold caspase activity was calculated as emission of sample cells/emission of control cells.
Western blot analysis
Cells were lysed in lysis buffer (50 mM Hepes, pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl 2 , 1 mM EGTA, 100 mM NaF, 10 mM pyrophosphate, 0.01% NaN 3 and Complete) by sonication. The protein content was determined with the DC Protein assay kit (Bio-Rad, Hercules, CA, USA), and 60 mg of the protein was subjected to 12-15% SDS-polyacrylamide gel electrophoresis, blotted onto nitrocellulose membranes and incubated with antibodies directed against caspase-3, IkBa (9662, L35A5; Cell Signaling Technology Inc., Danvers, MA, USA) FLIP L/S , xIAP (556567, 610716; BD Biosciences), a-tubulin (DM1A; Neomarkers) or b-actin (Sigma). After incubation with horseradish peroxidase-conjugated secondary antibodies (Amersham, Buckinghamshire, UK), detection was performed with the chemiluminescence SuperSignal system (Pierce Biotechnology Inc., Rockford, IL, USA). Densitometric protein expression was analysed with Image Quant software.
Semiquantitative PCR analysis
Total RNA was extracted from cells using GIT buffer followed by phenol/chloroform extraction and 1.5 mg of RNA reverse transcribed with an AMV Reverse Transcriptase kit (Promega, Madison, WI, USA). The following primers were used in a 20 ml reaction utilizing RedTaq polymerase system (Sigma): GAPDH-F, 5 0 -TgATgACATACCgAAggTggTgAAg-3 0 ; R, 5 0 -TCCTTggAggCCATgTAggCCAT-3 0 ; xIAP-F, 5 0 -gAAAA CTATCTgggAAgCAgAg-3 0 ; R, 5 0 -CgAATATTAAgATTCC ggCCCA-3 0 ; FLIP-F, 5 0 -CgAATATTAAgATTCCggCCCA-3 0 ; R, 5 0 -gAAAACTATCTgggAAgCAgAg-3 0 and bax-F, 5 0 -CTTCAgggTTTCATCCAggATC-3 0 ; R, 5 0 -TgATggTTCT gATCAgTTCCgg-3 0 .
